Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.81
-0.28 (-3.08%)
At close: Nov 7, 2025, 4:00 PM EST
8.93
+0.12 (1.36%)
After-hours: Nov 7, 2025, 7:37 PM EST
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $26.06M in the quarter ending September 30, 2025, with 605.36% growth. This brings the company's revenue in the last twelve months to $84.39M, up 244.60% year-over-year. In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%.
Revenue (ttm)
$84.39M
Revenue Growth
+244.60%
P/S Ratio
5.70
Revenue / Employee
$1,430,305
Employees
59
Market Cap
495.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
| Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ZVRA News
- 2 days ago - Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Zevra Reports Third Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 10 days ago - Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 12 days ago - Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call - GlobeNewsWire
- 4 weeks ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate) - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewsWire